**THE CHINA INTERNATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AWARDS FOUR SEED GRANTS**

Seed grant projects are excellent examples of The Center’s philosophy of supporting research training and local capacity development. We have awarded four seed research grants to investigators working on projects which connect one of our local Chinese partners and one or more of our international partners. We also hope to create long-term partnerships and strengthen existing relationships.

**2 – 5 October, 2011**

Invited by Duke Global Health Institute, Professor Lijing Yan, Director of the China International Center for Chronic Disease Prevention and Control, The George Institute for Global Health, Australia attended to the 5th International Symposium on ‘Global Health 2020: Acting today to improve tomorrow’ and a 40-minute lecture on the “Globalization of cardiovascular diseases in China and strategies taken by the China Center of Excellence.”

**10 – 12 October, 2011**

The Center of Excellence seed grant offers a platform for enhancing collaboration among the network of centers across the world, while developing local partners’ research capacity. On 10 – 12 November 2011, Dr Ruika Kampa Rauge from the University of Queensland visited the China center and provided two-day training course of our seed grant projects — Verbal Autopsy.

**15 – 22 January, 2012**

Mr Maxie To, a young research fellow at the China Center of Excellence was sponsored to attended the 4th Ten-Day International Health Training Seminar on Cardiovascular Disease Epidemiology and Prevention. This training opportunity was offered through graduate students, with full fee and no formal training in epidemiology.

**CRITICAL DIABETES RESEARCH LAUNCHED IN CHINA**

Diabetes is a major health and economic burden all around the world. China’s growing population is increasingly affected by diabetes, making the condition a pivotal healthcare issue. According to the International Diabetes Federation, the disease affects 1 in 10 adults in China, and costs nearly US$26 billion every year.

Many type 2 diabetes patients in China largely self-manage much later than recommended by Chinese guidelines. For many diabetic patients on insulin treatment, doses are suboptimal and parameters are not monitored properly.

The George Institute for Global Health China, the Chinese Diabetes Society, and Sanofi jointly launched the ORBIT (Observational Registry for Basal Insulin Treatment) study on 23 November 2011 in Beijing.

**22 – 26 October, 2011**

The China International Center for Chronic Disease Prevention and Control (ORBIT) study on 23 November 2011 in Beijing:

**2 – 5 October, 2011**

Invited by Duke Global Health Institute, Professor Lijing Yan, Director of the China International Center for Chronic Disease Prevention and Control, The George Institute for Global Health, Australia attended to the 5th International Symposium on ‘Global Health 2020: Acting today to improve tomorrow’ and a 40-minute lecture on the “Globalization of cardiovascular diseases in China and strategies taken by the China Center of Excellence.”

**10 – 12 October, 2011**

The Center of Excellence seed grant offers a platform for enhancing collaboration among the network of centers across the world, while developing local partners’ research capacity. On 10 – 12 November 2011, Dr Ruika Kampa Rauge from the University of Queensland visited the China center and provided two-day training course of our seed grant projects — Verbal Autopsy.

**15 – 22 January, 2012**

Mr Maxie To, a young research fellow at the China Center of Excellence was sponsored to attended the 4th Ten-Day International Health Training Seminar on Cardiovascular Disease Epidemiology and Prevention. This training opportunity was offered through graduate students, with full fee and no formal training in epidemiology.

**CRITICAL DIABETES RESEARCH LAUNCHED IN CHINA**

Diabetes is a major health and economic burden all around the world. China’s growing population is increasingly affected by diabetes, making the condition a pivotal healthcare issue. According to the International Diabetes Federation, the disease affects 1 in 10 adults in China, and costs nearly US$26 billion every year.

Many type 2 diabetes patients in China largely self-manage much later than recommended by Chinese guidelines. For many diabetic patients on insulin treatment, doses are suboptimal and parameters are not monitored properly.

The George Institute for Global Health China, the Chinese Diabetes Society, and Sanofi jointly launched the ORBIT (Observational Registry for Basal Insulin Treatment) study on 23 November 2011 in Beijing.

**22 – 26 October, 2011**

The China International Center for Chronic Disease Prevention and Control (ORBIT) study on 23 November 2011 in Beijing:

**2 – 5 October, 2011**

Invited by Duke Global Health Institute, Professor Lijing Yan, Director of the China International Center for Chronic Disease Prevention and Control, The George Institute for Global Health, Australia attended to the 5th International Symposium on ‘Global Health 2020: Acting today to improve tomorrow’ and a 40-minute lecture on the “Globalization of cardiovascular diseases in China and strategies taken by the China Center of Excellence.”

**10 – 12 October, 2011**

The Center of Excellence seed grant offers a platform for enhancing collaboration among the network of centers across the world, while developing local partners’ research capacity. On 10 – 12 November 2011, Dr Ruika Kampa Rauge from the University of Queensland visited the China center and provided two-day training course of our seed grant projects — Verbal Autopsy.

**15 – 22 January, 2012**

Mr Maxie To, a young research fellow at the China Center of Excellence was sponsored to attended the 4th Ten-Day International Health Training Seminar on Cardiovascular Disease Epidemiology and Prevention. This training opportunity was offered through graduate students, with full fee and no formal training in epidemiology.

**CRITICAL DIABETES RESEARCH LAUNCHED IN CHINA**

Diabetes is a major health and economic burden all around the world. China’s growing population is increasingly affected by diabetes, making the condition a pivotal healthcare issue. According to the International Diabetes Federation, the disease affects 1 in 10 adults in China, and costs nearly US$26 billion every year.

Many type 2 diabetes patients in China largely self-manage much later than recommended by Chinese guidelines. For many diabetic patients on insulin treatment, doses are suboptimal and parameters are not monitored properly.

The George Institute for Global Health China, the Chinese Diabetes Society, and Sanofi jointly launched the ORBIT (Observational Registry for Basal Insulin Treatment) study on 23 November 2011 in Beijing.

**22 – 26 October, 2011**

The China International Center for Chronic Disease Prevention and Control (ORBIT) study on 23 November 2011 in Beijing:
High-quality execution of the study is critical in delivering the most scientific and rigorous outcome. Thus, The George Institute has established a dedicated team for the research of basal insulin therapy can help improve diabetes treatment within the healthcare system, and remain cost-effective, is unclear. Establishing a strong support system at the hospital level and ensuring that physicians, nurses, and patients have enough information on diabetes management are key that ORBIT is addressing. Working with patients, physicians, and the public over 18 months, some of the first results are expected to be delivered by the end of 2018.

The study was initiated by the CDS and conducted by the George Institute for Global Health, China, with the financial support of Sanofi.

**Top: Professor Wu Yangfeng answers a question from the media during Q&A in the picture.**

**Above: ORBIT is jointly launched by The George Institute China, Chinese Diabetes Society and Sanofi-Aventis.**

**DIABETES FEDERATION**

**VICE PRESIDENT OF INTERNATIONAL**

**Professor Ji Linong, has been elected the President of the Chinese Diabetes Society (CDS) and Principal Investigator of the ORBIT study.**

**President of the Chinese Diabetes Society (CDS) and Principal Investigator of the ORBIT study.**

**China warmly congratulates Professor Ji on this recent appointment as Vice President of IDF and looks forward to exciting and innovative work in diabetes research in the future.**

**Centers of Excellence Team up to Improve Cardiovascular Health in Tibet and India**

The SimCard study will examine the factors associated with cardiovascular health in Tibet and India and involve 20,000 type 2 diabetes patients nationwide. The ORBIT is the largest study on basal insulin ever conducted in China, involving 15,000 participants from more than 170 clinical sites. It is expected that the study will be a milestone in basal insulin treatment in clinical practice for type 2 diabetes and shed light on diabetes control and management in China,” said Professor JI Linong, President of the Chinese Diabetes Society (CDS) and Principal Investigator of the ORBIT study.

**The George Institute for Global Health China, Beijing, China**

**As an international organisation with a strong local base, The George Institute for Global Health China, is well positioned to serve as a host organisation to provide solid training for visiting fellows, visiting scholars and student interns interested in clinical, population, health system, and translational research. We will engage visiting fellows in a satisfying and enriching training experience for our visiting scholars, fellows and student interns.**

**For more information about these events:**

[http://www.georgeinstitute.org.cn](http://www.georgeinstitute.org.cn)

**China International Center for Chronic Disease Prevention’s information on fellows or contact CD-Center@ georgeinstitute.org.cn.**

**Who knows? Maybe The George in India or the UK could be next.**